Cargando…

The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis

Liver fibrosis develops in response to chronic toxic or cholestatic injury, and is characterized by apoptosis of damaged hepatocytes, development of inflammatory responses, and activation of Collagen Type I producing myofibroblasts that make liver fibrotic. Two major cell types, Hepatic Stellate Cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuji, Hiroaki, Miller, Grant, Nishio, Takahiro, Koyama, Yukinori, Lam, Kevin, Zhang, Vivian, Loomba, Rohit, Brenner, David, Kisseleva, Tatiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710774/
https://www.ncbi.nlm.nih.gov/pubmed/34966784
http://dx.doi.org/10.3389/fmolb.2021.790032
_version_ 1784623234713387008
author Fuji, Hiroaki
Miller, Grant
Nishio, Takahiro
Koyama, Yukinori
Lam, Kevin
Zhang, Vivian
Loomba, Rohit
Brenner, David
Kisseleva, Tatiana
author_facet Fuji, Hiroaki
Miller, Grant
Nishio, Takahiro
Koyama, Yukinori
Lam, Kevin
Zhang, Vivian
Loomba, Rohit
Brenner, David
Kisseleva, Tatiana
author_sort Fuji, Hiroaki
collection PubMed
description Liver fibrosis develops in response to chronic toxic or cholestatic injury, and is characterized by apoptosis of damaged hepatocytes, development of inflammatory responses, and activation of Collagen Type I producing myofibroblasts that make liver fibrotic. Two major cell types, Hepatic Stellate Cells (HSCs) and Portal Fibroblasts (PFs) are the major source of hepatic myofibroblasts. Hepatotoxic liver injury activates Hepatic Stellate Cells (aHSCs) to become myofibroblasts, while cholestatic liver injury activates both aHSCs and Portal Fibroblasts (aPFs). aPFs comprise the major population of myofibroblasts at the onset of cholestatic injury, while aHSCs are increasingly activated with fibrosis progression. Here we summarize our current understanding of the role of aPFs in the pathogenesis of cholestatic fibrosis, their unique features, and outline the potential mechanism of targeting aPFs in fibrotic liver.
format Online
Article
Text
id pubmed-8710774
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87107742021-12-28 The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis Fuji, Hiroaki Miller, Grant Nishio, Takahiro Koyama, Yukinori Lam, Kevin Zhang, Vivian Loomba, Rohit Brenner, David Kisseleva, Tatiana Front Mol Biosci Molecular Biosciences Liver fibrosis develops in response to chronic toxic or cholestatic injury, and is characterized by apoptosis of damaged hepatocytes, development of inflammatory responses, and activation of Collagen Type I producing myofibroblasts that make liver fibrotic. Two major cell types, Hepatic Stellate Cells (HSCs) and Portal Fibroblasts (PFs) are the major source of hepatic myofibroblasts. Hepatotoxic liver injury activates Hepatic Stellate Cells (aHSCs) to become myofibroblasts, while cholestatic liver injury activates both aHSCs and Portal Fibroblasts (aPFs). aPFs comprise the major population of myofibroblasts at the onset of cholestatic injury, while aHSCs are increasingly activated with fibrosis progression. Here we summarize our current understanding of the role of aPFs in the pathogenesis of cholestatic fibrosis, their unique features, and outline the potential mechanism of targeting aPFs in fibrotic liver. Frontiers Media S.A. 2021-12-13 /pmc/articles/PMC8710774/ /pubmed/34966784 http://dx.doi.org/10.3389/fmolb.2021.790032 Text en Copyright © 2021 Fuji, Miller, Nishio, Koyama, Lam, Zhang, Loomba, Brenner and Kisseleva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Fuji, Hiroaki
Miller, Grant
Nishio, Takahiro
Koyama, Yukinori
Lam, Kevin
Zhang, Vivian
Loomba, Rohit
Brenner, David
Kisseleva, Tatiana
The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title_full The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title_fullStr The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title_full_unstemmed The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title_short The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis
title_sort role of mesothelin signaling in portal fibroblasts in the pathogenesis of cholestatic liver fibrosis
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710774/
https://www.ncbi.nlm.nih.gov/pubmed/34966784
http://dx.doi.org/10.3389/fmolb.2021.790032
work_keys_str_mv AT fujihiroaki theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT millergrant theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT nishiotakahiro theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT koyamayukinori theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT lamkevin theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT zhangvivian theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT loombarohit theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT brennerdavid theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT kisselevatatiana theroleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT fujihiroaki roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT millergrant roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT nishiotakahiro roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT koyamayukinori roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT lamkevin roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT zhangvivian roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT loombarohit roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT brennerdavid roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis
AT kisselevatatiana roleofmesothelinsignalinginportalfibroblastsinthepathogenesisofcholestaticliverfibrosis